Signal transduction

Breast Cancer Society of Canada Grants $250,000 To Precision Oncology Research at Dalhousie University

Retrieved on: 
Wednesday, June 15, 2022
Breast cancer, Signal transduction, Department, Reynolds cancer charities, World, Biochemistry, HER2, Harvard Medical School, BCSC, Dalhousie University, CEO, Breast, MIT, Ontario Cancer Institute, Precision medicine, Recurrence, Cancer, Lunenfeld-Tanenbaum Research Institute, Research, Columbia Senior Executive Program, Molecular biology, Faculty, JHSPH Department of Biochemistry and Molecular Biology, Biomarker, Division of Signal Transduction Therapy, Artificial intelligence, World Health Organization, Medical school, Patient, Diagnosis, GLOBE, Division, Pharmaceutical industry, Medical imaging, Medicine

The overarching goal of the research project is to identify new biomarkers that distinguish recurrence potential from HER2+ breast cancer.

Key Points: 
  • The overarching goal of the research project is to identify new biomarkers that distinguish recurrence potential from HER2+ breast cancer.
  • The breast cancer research projects that have been selected for funding will aim to advance screening, detection, precision oncology and patient reported outcomes, enhancing care for Canadians with breast cancer.
  • Kimberly Carson, CEO of the Breast Cancer Society of Canada, said, Dr. Marignanis research will directly impact the lives of breast cancer patients by developing treatment plans that are tailored to the individual.
  • The Breast Cancer Society of Canada (BCSC) is a registered, national, non-profit, charitableorganization dedicated to saving lives through breast cancer research.

Domain Therapeutics Appoints Dr Xavier Leroy as Chief Scientific Officer

Retrieved on: 
Monday, June 13, 2022
Oncology, Health, Medical Devices, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, IO, Goal, J&J, European Cooperation in Science and Technology, Research, CTO, Knowledge, G protein-coupled receptor, CEO, GPCR, Gq alpha subunit, Inflammation, Adenosine, Nasdaq, Multimedia, Therapy, Novartis, CSO, Drug discovery, COST, Signal transduction, Fine chemical, Pharmaceutical industry, Science, European, Technology

Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), today announced that it is strengthening its scientific team with the appointement of Dr Xavier Leroy as CSO.

Key Points: 
  • Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), today announced that it is strengthening its scientific team with the appointement of Dr Xavier Leroy as CSO.
  • View the full release here: https://www.businesswire.com/news/home/20220613005393/en/
    Based on his widely recognized expertise in GPCRs and immunology, Dr Leroy joined Domain Therapeutics as Chief Technology Officer (CTO) in 2019 to identify and select strategic targets to expand the immuno-oncology pipeline of the company.
  • From now on, Xavier Leroy will lead the Research and will be in charge of turning the company into a clinical stage biopharma.
  • The prospect of bringing into clinic first-in-class candidates targeting brand new GPCRs in immuno-oncology is very exciting, said Dr Xavier Leroy.

Adcendo Appoints Dominik Mumberg, PhD, as Chief Scientific Officer

Retrieved on: 
Tuesday, May 3, 2022
Antibody, HealthCap, Signal transduction, Schering AG, Mesenchyme, Soft-tissue sarcoma, ADC, Mesothelioma, Bayer, University, Stanford University, CSO, GBM, CTO, Control, Osteosarcoma, University of Marburg, SAB, Research, Glioblastoma, CDO, EUR, Schering, Patient, Doctor of Philosophy, Finsen Laboratory, Mannose, Cancer, Chicago (franchise), Knowledge, Copenhagen, Leadership, United States Air Force Scientific Advisory Board, Apoptosis, Prostate Cancer Foundation, Kinetics, VP, Novo Holdings A/S, Rigshospitalet, Cell, Molecular biology, Fine chemical, Medical imaging

Before his time at Bayer, Dominik was Director, Apoptosis & Signal Transduction Research at Schering AG.

Key Points: 
  • Before his time at Bayer, Dominik was Director, Apoptosis & Signal Transduction Research at Schering AG.
  • Michael Pehl, Chief Executive Officer of Adcendo, said: "We are very excited to welcome Dominik to the Adcendo team.
  • Dominik Mumberg, Chief Scientific Officer of Adcendo, commented: "I am very pleased to join Adcendo at this important stage of corporate development.
  • This latest addition to Adcendo's leadership team follows the recent appointments of Carmel M. Lynch, PhD, as Chief Development Officer (CDO), Pernille Hyrup Hemmingsen, PhD, as Chief Technology Officer (CTO) and Dennis Benjamin, PhD as Research Fellow & Chair of the Scientific Advisory Board (SAB).

Adcendo Appoints Dominik Mumberg, PhD, as Chief Scientific Officer

Retrieved on: 
Tuesday, May 3, 2022
Antibody, HealthCap, Signal transduction, Schering AG, Mesenchyme, Soft-tissue sarcoma, ADC, Mesothelioma, Bayer, University, Stanford University, CSO, GBM, CTO, Control, Osteosarcoma, University of Marburg, SAB, Research, Glioblastoma, CDO, EUR, Schering, Patient, Doctor of Philosophy, Finsen Laboratory, Mannose, Cancer, Chicago (franchise), Knowledge, Copenhagen, Leadership, United States Air Force Scientific Advisory Board, Apoptosis, Prostate Cancer Foundation, Kinetics, VP, Novo Holdings A/S, Rigshospitalet, Cell, Molecular biology, Fine chemical, Medical imaging

Before his time at Bayer, Dominik was Director, Apoptosis & Signal Transduction Research at Schering AG.

Key Points: 
  • Before his time at Bayer, Dominik was Director, Apoptosis & Signal Transduction Research at Schering AG.
  • Michael Pehl, Chief Executive Officer of Adcendo, said: "We are very excited to welcome Dominik to the Adcendo team.
  • Dominik Mumberg, Chief Scientific Officer of Adcendo, commented: "I am very pleased to join Adcendo at this important stage of corporate development.
  • This latest addition to Adcendo's leadership team follows the recent appointments of Carmel M. Lynch, PhD, as Chief Development Officer (CDO), Pernille Hyrup Hemmingsen, PhD, as Chief Technology Officer (CTO) and Dennis Benjamin, PhD as Research Fellow & Chair of the Scientific Advisory Board (SAB).

Preclinical Immunotherapy Research Featured in Poster Presentation at AACR 2022 Annual Meeting Highlights YIV-906’s Immunomodulatory Mechanisms in Combination with Immune Checkpoint or CAR T Therapy

Retrieved on: 
Friday, April 8, 2022
Memorial Sloan Kettering Cancer Center, Method, CGMP, Quality control, Therapy, Systems biology, Immunotherapy, Sorafenib, Liver, Tumor microenvironment, Biotechnology, COX2, Hepatocellular carcinoma, NF, Cancer, WNT, Food, Inflammation, Wnt signaling pathway, Queen Mary's Hospital, Orphan drug, Signal transduction, Gastrointestinal tract, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, HCC, Yale University, IL-6, Taipei Medical University, FDA, Pancreatic cancer, Patient, M1, Pharmaceutical industry

NEW HAVEN, Conn and NEW YORK and SHANGHAI, April 08, 2022 (GLOBE NEWSWIRE) -- Yiviva and Yale scientists will present new data from Yiviva’s oncology portfolio at the 2022 American Association for Cancer Research (AACR) Annual Meeting in New Orleans on April 8-13, 2022.

Key Points: 
  • YIV-906 has the potential to be developed as a platform oncology therapeutic when administered in combination with chemotherapy, immunotherapy and radiation therapies, in multiple cancer indications.
  • YIV-906 has shown promise in preliminary clinical studies in liver, pancreatic, colorectal and rectal cancers.
  • Yiviva is a clinical stage, platform biotechnology company developing multi-targeted, systems biology therapeutics, focused on cancer and inflammatory diseases.
  • The company was launched with Yale University as a co-founder and co-founders include Yung Chi Cheng, Ph.D. For further information, please visit https://yiviva.com .

Kither Biotech announces publication of new data in Science Translational Medicine

Retrieved on: 
Thursday, March 31, 2022
Company, CFTR, Cell, Idiopathic pulmonary fibrosis, CF, Epithelium, SCI, Camp, Science Translational Medicine, Respiratory disease, Cystic fibrosis transmembrane conductance regulator, CEO, Cystic fibrosis, University of Turin, Pulmonology, MP, Bronchoconstriction, Degenerative disease, Inflammation, Signal transduction, DOI, COPD, Asthma, PKA, University, Patient, Disease, Pharmaceutical industry

Vincent Metzler, CEO at Kither Biotech, commented: The publication of these data in a prominent peer-reviewed journal represents an important step as we advance the development of KIT2014 for the treatment of cystic fibrosis as an add-on therapy to CFTR modulators.

Key Points: 
  • Vincent Metzler, CEO at Kither Biotech, commented: The publication of these data in a prominent peer-reviewed journal represents an important step as we advance the development of KIT2014 for the treatment of cystic fibrosis as an add-on therapy to CFTR modulators.
  • Kither Biotech is a biopharma company founded by Prof. Alessandra Ghigo, Prof. Emilio Hirsch, Prof. Alberto Bardelli and Marco Kevin Malisani.
  • Kither Biotech is a spin-off from the University of Turin and actively collaborates with the Molecular Biotechnology Center (University of Turin) and other research centres in the world.
  • In CF patients, treatment with KIT2014 is believed to restore the function of CFTR mutants by potentiating the effects of CFTR modulators (Ghigo et al., Science Translational Medicine, in press).

Kanazawa University research: Changing the handedness of molecules

Retrieved on: 
Wednesday, March 9, 2022
National academy, SCI, Achievement, III, Signal transduction, Science, Nitrogen, Kanazawa University, Complex, Relaxation, National, Transience, Fine chemical, Proc

KANAZAWA, Japan, March 9, 2022 /PRNewswire/ -- Researchers at Kanazawa University report in Proceedings of the National Academy of Sciences a responsive molecular system that, through chemical reactions, inverses its chirality before becoming racemic.

Key Points: 
  • KANAZAWA, Japan, March 9, 2022 /PRNewswire/ -- Researchers at Kanazawa University report in Proceedings of the National Academy of Sciences a responsive molecular system that, through chemical reactions, inverses its chirality before becoming racemic.
  • chemical oscillators (whose structure switches periodically between two states), offer advanced functionalities and are also intensively investigated.Shigehisa Akine and colleagues from Kanazawa University have now designed a particular responsive molecule in which the chirality ('handedness') changes in a non-exponential fashion.
  • Shigehisa Akine and colleagues from Kanazawa University have now discovered a molecular system in solution that, through chemical reactions, changes its overall 'handedness' (chirality) from right to left, before becoming racemic.
  • Yoko Sakata, Shunsuke Chiba, and Shigehisa Akine,Transient Chirality Inversion during Racemization of a Helical Cobalt (III) Complex, Proc.

Kanazawa University research: Changing the handedness of molecules

Retrieved on: 
Wednesday, March 9, 2022
National academy, SCI, Achievement, III, Signal transduction, Science, Nitrogen, Kanazawa University, Complex, Relaxation, National, Transience, Fine chemical, Proc

KANAZAWA, Japan, March 9, 2022 /PRNewswire/ -- Researchers at Kanazawa University report in Proceedings of the National Academy of Sciences a responsive molecular system that, through chemical reactions, inverses its chirality before becoming racemic.

Key Points: 
  • KANAZAWA, Japan, March 9, 2022 /PRNewswire/ -- Researchers at Kanazawa University report in Proceedings of the National Academy of Sciences a responsive molecular system that, through chemical reactions, inverses its chirality before becoming racemic.
  • chemical oscillators (whose structure switches periodically between two states), offer advanced functionalities and are also intensively investigated.Shigehisa Akine and colleagues from Kanazawa University have now designed a particular responsive molecule in which the chirality ('handedness') changes in a non-exponential fashion.
  • Shigehisa Akine and colleagues from Kanazawa University have now discovered a molecular system in solution that, through chemical reactions, changes its overall 'handedness' (chirality) from right to left, before becoming racemic.
  • Yoko Sakata, Shunsuke Chiba, and Shigehisa Akine,Transient Chirality Inversion during Racemization of a Helical Cobalt (III) Complex, Proc.

Polymyalgia Rheumatica Drug Pipeline Market Research Report 2021 Featuring Bristol-Myers Squibb, AbbVie, Eli Lilly and Co, & Sparrow Pharmaceuticals - ResearchAndMarkets.com

Retrieved on: 
Friday, March 4, 2022
Health, Pharmaceutical, Route of administration, Signal transduction, Glucocorticoid, News, Administration, Tocilizumab, II, PMR, Route, Interleukin, Clinical trial, Discovery, IL-6, Therapy, Oil, Pharmaceutical industry, Polymyalgia rheumatica

The "Polymyalgia Rheumatica - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Polymyalgia Rheumatica - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Polymyalgia Rheumatica - Pipeline Insight, 2021" report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Polymyalgia Rheumatica pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Polymyalgia Rheumatica R&D.
  • Polymyalgia Rheumatica pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

AmMax Bio Announces the Appointment of Biotechnology Executive, Michael Kavanaugh, M.D., as Independent Board Member

Retrieved on: 
Thursday, February 24, 2022
Giant, GLOBE, Risk, Therapy, Board of directors, Tenosynovial giant cell tumor, Cell, Board, CSF1, Pain, IPF, Disability, University, Novartis, Industry, University of California, San Francisco, Drug development, TGCT, Signal transduction, Coronavirus Scientific Advisory Board (Turkey), CSF1R, Biotechnology, Independent Board for Presbyterian Foreign Missions, Patient, Quality of life, Macrophage, Idiopathic pulmonary fibrosis, Program, Incidence, Infection, Health, Pharmaceutical industry, Chiron, Amgen, Medicine

We are very pleased to welcome Dr. Kavanaugh to our Board of Directors, said Larry Hsu, Ph.D., Chairman of the Board and Chief Executive Officer of AmMax Bio.

Key Points: 
  • We are very pleased to welcome Dr. Kavanaugh to our Board of Directors, said Larry Hsu, Ph.D., Chairman of the Board and Chief Executive Officer of AmMax Bio.
  • We welcome Michael to our Board and look forward to benefiting from his future contributions.
  • "I am very happy to join the Board of AmMax Bio, said Michael Kavanaugh, M.D.
  • Based on robust preclinical proof-of-concept results, AmMax is also planning to initiate a Phase 2 clinical study in idiopathic pulmonary fibrosis (IPF).